Welcome to our dedicated page for Can-Fite BioPharma news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) announced the publication of a scientific paper on its drug Namodenoson for advanced hepatocellular carcinoma (HCC) with Child-Pugh B cirrhosis. Although the Phase II trial did not meet its primary endpoint, it showed significant survival benefits for patients with a CPB score of 7, with some patients remaining under treatment for over 3.5 years. The FDA and EMA have approved the protocol for a Phase III study. Namodenoson has received Orphan Drug and Fast Track Designation from the FDA.
Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) has received approval from Israel's Ministry of Health to conduct pre-clinical studies on cannabinoid fractions at nanomolar concentrations. This assessment aims to explore effects on cancer, inflammatory, and fat cells, potentially minimizing the adverse effects associated with higher concentrations. Can-Fite's research will be conducted in its labs, utilizing patent-pending formulations and assays. The medical cannabis market, projected to grow at a CAGR of 29%, positions Can-Fite strategically for advancements in this emerging field.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced progress on its drug candidate Namodenoson for treating non-alcoholic steatohepatitis (NASH). The company is designing a Phase IIb study with expert collaboration, following a successful Phase II study. Manufacturing for the clinical trial is complete, and new NASH patents have been issued. Namodenoson is licensed for distribution in Korea and China, targeting a growing market projected at $35-40 billion by 2025. Current estimates indicate 17%-33% of the U.S. population has non-alcoholic fatty liver disease (NAFLD), emphasizing the urgent medical need.
Can-Fite BioPharma (NYSE American: CANF) announced its participation in the 12th annual LD 500 Virtual Conference, scheduled for September 1, 2020. CEO Dr. Pnina Fishman will present at 9:20 AM EST and conduct private meetings with investors. The event aims to attract around 20,000 attendees and features 300 companies. Can-Fite plans to update on its advanced pipeline, including Phase III trials for rheumatoid arthritis, psoriasis, and liver cancer, alongside new studies for COVID-19 and NAFLD/NASH. Investors can register to view the presentation online.